Biosimilars

The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.

Latest News

Market share increase | Image Credit: Kiattisak - stock.adobe.com
Samsung Bioepis Reports 2024 Biosimilar Market Growth Trends

October 15th 2024

Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.

FDA approve graphic on screen over a doctor | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Imuldosa, a Fifth Biosimilar to Stelara

October 11th 2024

Cost reduction in health care. | Image Credit: wladimir1804 - stock.adobe.com
Blue Shield of California Lowers Humira Biosimilar Costs, Challenges PBM Pricing

October 7th 2024

Blue FDA approved stamp | Image credit: cartoon-stock - adobe.com
Fourth Ustekinumab Biosimilar, Otulfi, Approved in US

October 2nd 2024

Follitropin alfa | Image Credit: cristianstorto - stock.adobe.com
Biosimilar Follitropin Alfa Offers Fertility Savings in France

September 30th 2024

Continuing Medical Education
View All
October 23rd 2024

Managed Care Pharmacy: A Plan for the Future and How Pharmacists Are Leading the Way

0.5 Credits / General Pharmacy

More News

Purva Rawal, PhD
February 21st 2022

CMS Official Cites OCM as Example of Biosimilar Success

Mary Caffrey
Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, addressed attendees at the Association for Accessible Medicines' Access! annual meeting, held in Orlando, Florida, February 15-16.
health care cost
February 16th 2022

Biosimilars Available for 3 Drugs Costing More Through Hospitals, Physicians

Laura Joszt, MA
AHIP released a report looking at the price markups for 10 drugs that can be delivered more affordably through specialty pharmacies, including 3 drugs with multiple biosimilars available.
syringe stuck in a vial
February 14th 2022

A Review of Biosimilars in 2021: Regulatory, Legal Developments, and What’s in Store for the New Year

Skylar Jeremias
Although the COVID-19 pandemic has led to mass slowdowns in drug approvals and biosimilar launches, 2021 signaled a stronger focus on biosimilars going forward, with new regulatory bills and a crackdown on anticompetitive practices.
Remsima
February 11th 2022

VA Study: Patients Switching to Biosimilar Infliximab More Likely to Stop Treatment

Mary Caffrey
Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, despite the cost savings that can be achieved.
Site Logo
February 9th 2022

Real-world Usage of Bevacizumab-bvzr Biosimilar in US Oncology Practice

Jingyan Yang, DrPH, MHS John Mark Kelton, PharmD Jeffrey Thompson, PhD Jose Maria Jimenez Alvir, DrPH Martine C. Maculaitis, PhD Ahmed Shelbaya, MD
Real-world adoption of bevacizumab-bvzr biosimilar was retrospectively assessed, revealing switching between biosimilars and the reference product and utilization in extrapolated indications and combination regimens.
Bruce Feinberg, DO
February 8th 2022

Payers, Value-based Care Policies Impact Biosimilar Adoption, Cardinal Health Report Finds

Mary Caffrey
Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.
Kathy Oubre, MS
February 4th 2022

Kathy Oubre: How Biosimilars Have Helped Reduce Financial Toxicity in Cancer Care

Skylar Jeremias
Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, talks about how biosimilars have been able to help patients avoid financial toxicity related to oncology care costs.
vials
February 3rd 2022

Mandatory Biosimilar Switch in Canada Has Minimal Impacts on Patient Health

Laura Joszt, MA
The Biosimilars Initiative in British Columbia, Canada, mandated patients with certain conditions on the province’s prescription coverage plan to switch from originator etanercept to a biosimilar.
molecules
January 28th 2022

Biogen Sells Stake in Biosimilar Venture Samsung Bioepis

Laura Joszt, MA
Biogen is selling its stake in the biosimilar joint venture to Samsung Bioepis for up to $2.3 billion after first investing in 2012.
Ryan Haumschild (top left), Sonia Oskouei (top center), CfB's Tony Hagen (top right), Madelaine Feldman (bottom left), and Sameer Awsare (bottom right)
January 26th 2022

Panelists Explore What Exactly Is Holding Up US Adoption of Biosimilars

Skylar Jeremias
Payer intervention, lack of patient savings, and confusion surrounding interchangeability are some of the many barriers standing in the way of US biosimilar uptake, with our group of panelists calling for big changes.
gavel sitting on a scale
January 21st 2022

Patents Filed a Decade Post Originator Approval Account for Most Biosimilar Patent Lawsuits

Skylar Jeremias
Researchers have found that most US patent infringement cases against biosimilar manufacturers cover patents filed over a decade after the originator product's FDA approval, leading to limits on competition among biologic drugs.
blue molecules
January 19th 2022

Trastuzumab Biosimilar Has Similar Efficacy, Safety to Reference Product in Advanced Gastric Cancer

Laura Joszt, MA
The trastuzumab biosimilar Herzuma was shown to have similar clinical efficacy and safety to the reference product in patients with HER2-positive advanced gastric cancer.
rows of vials
January 15th 2022

US Uptake of Biosimilars Remains Suboptimal and Requires Intervention

Laura Joszt, MA
Compared with the European Union, biosimilar use in the United States lags, and the US government, health systems, and medical associations all have a role to play.
woman who is out of focus except for her eye
January 12th 2022

Ophthalmology Biobetters and Biosimilars May Be Just Around the Corner

Skylar Jeremias
More biobetter drugs may be on the horizon, with an opportunity to snatch market share from reference products, and several biosimilars are under development for ophthalmic conditions, authors of a review concluded.
Approvals, Policy Changes Raise Profile of Biosimilars in Canada
January 4th 2022

Approvals, Policy Changes Raise Profile of Biosimilars in Canada

Tony Hagen
At least 8 biosimilars were approved in Canada over the past 12 months, as policy makers made a strong push for biosimilar acceptance, which led to a change in prescribing patterns.
Site Logo
January 3rd 2022

Projected US Savings From Biosimilars, 2021-2025

Andrew Mulcahy, PhD, MPP Christine Buttorff, PhD Kenneth Finegold, PhD Zeid El-Kilani, MPP Jon F. Oliver, PhD Stephen Murphy, PhD Amber Jessup, PhD
Projected savings from biosimilars from 2021 to 2025 were $38.4 billion vs conditions as of quarter 4 of 2020 and were driven by new biosimilar entry. Savings were $124.5 billion under an upper-bound scenario.
Yusimry, the Seventh Adalimumab Biosimilar, Gains FDA Approval
December 26th 2021

Yusimry, the Seventh Adalimumab Biosimilar, Gains FDA Approval

Laura Joszt, MA
Despite being the seventh adalimumab biosimilar approved in the United States, there are none on the market yet.
Top biosimilars articles
December 22nd 2021

Top 5 Most-Read Biosimilars News of 2021

Laura Joszt, MA
This year the United States only approved 2 biosimilars, but the FDA did grant interchangeable status to the first biosimilar.
No Easy Path to Market for Alvotech's Adalimumab Biosimilar
December 20th 2021

No Easy Path to Market for Alvotech's Adalimumab Biosimilar

Tony Hagen
In hopes of protecting its lucrative adalimumab (Humira) franchise, AbbVie is mounting a hefty legal defense against Alvotech's adalimumab biosimilar candidate.
Findings Are Reported From De-Escalation Therapy in Early Breast Cancer
December 15th 2021

Findings Are Reported From De-escalation Therapy in Early Breast Cancer

Tony Hagen
Investigators said pathologic complete response was higher with a molecularly selected subgroup of patients with early-stage breast cancer treated with a nonchemotherapy combination that included a trastuzumab biosimilar.
Surveys Probe Biosimilars in Oncology
December 13th 2021

Surveys Probe Biosimilars in Oncology

Tony Hagen
Recent surveys shed light on oncologist and patient perceptions of the switch to biosimilars and patient mental health.
Investigators Estimate Cost of Extending HER2-Directed Therapy With Biosimilars in British Columbia
December 8th 2021

Investigators Estimate Cost of Extending HER2-Directed Therapy With Biosimilars in British Columbia

Tony Hagen
Costs of extending human epidermal growth factor receptor 2 (HER2) therapy for patients with metastatic breast cancer were estimated in a retrospective study.
Investigators Initiate Post-Trastuzumab Trial of GLSI-100 in Patients With Invasive Breast Cancer
December 7th 2021

Investigators Initiate Post-Trastuzumab Trial of GLSI-100 in Patients With Invasive Breast Cancer

Tony Hagen
Investigators hope to duplicate promising phase 2b trial results with an experimental peptide vaccine in a population of nearly 500 patients with human epidermal growth factor receptor 2 breast cancer.
an image of a humira pen and box with a gun sight over it
December 2nd 2021

Field of Potential Adalimumab Biosimilar Contenders Continues to Grow

Tony Hagen
The list of potential adalimumab biosimilars has now lengthened to 10, according to a Cardinal Health summary of these products and their distinguishing features.
Opinion: Higher Biosimilar Savings Are Possible Under Medicare Part B
November 30th 2021

Proponents of Uniform Billing Codes for Biosimilars Cite Generic Savings Success

Tony Hagen
Generics and biosimilars are reimbursed differently, causing providers to prefer lower-cost generics and higher-priced biologics, authors of a study and opinion piece contend.
AMCP Nexus Survey: Two-Thirds of Payers Use Biosimilars to Manage Oncology Drug Costs
November 23rd 2021

AMCP Nexus Survey: Two-Thirds of Payers Use Biosimilars to Manage Oncology Drug Costs

Laura Joszt, MA
As the cost of oncology drugs increases, there has been a growing pressure to manage oncology drug spend, which some payers have done by establishing preferred therapies, including biosimilars.
EU and WHO Authorities "Tailor" the Biosimilar Development Process
November 23rd 2021

EMA and WHO "Tailor" the Biosimilar Development Process

Tony Hagen
The European Medicines Agency (EMA) reports on progress to create a smoother, less wasteful biosimilar development process; and the World Health Organization (WHO) revises its biosimilar development guidelines.
AAM Panel of Manufacturers Say Drug Price Rebates Must Go
November 16th 2021

AAM Panel of Manufacturers Says Drug Price Rebates Must Go

Tony Hagen
Sandoz, Lupin, and Biocon Biologics representatives at the Association for Accessible Medicines (AAM) GRx+Biosims conference said that drug price rebates hinder biosimilar competition.
COA Reports on Biosimilar Patient Access, Payer Barriers
November 15th 2021

COA Reports Improved Biosimilar Access in Oncology

Tony Hagen
For trastuzumab and bevacizumab, biosimilars now represent a high share of administrations, but payer policies still hinder uptake of these products, the Community Oncology Alliance (COA) reports.
Alvotech Is Among Companies Leading the Charge for Interchangeables
November 11th 2021

Biosimilar Interchangeability: What's in a Name?

Tony Hagen
There is now a mad scramble to gain interchangeable status for biosimilars, but the meaning and significance of this appellation haven't yet been worked out for health care consumers or the manufacturing community.
<1
...
34567891011
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo